Answers are grounded in this paper and cite their sources.
Sir We are concerned with the conclusion that sentinel lymph node biopsy (SLNB) is an accurate staging investigation of the axilla following primary chemotherapy. The 21 trials studied varied considerably in entry criteria, the systemic therapies delivered and the method of axillary assessment used. The reported pooled sensitivity of 88 per cent, when breast surgeons aspire to a false negative rate of 5 per cent, could result in considerable understaging. Only ten of the trials cited achieved a false negative rate of less than 10 per cent, of which the highest three included fewer than 40 patients. Whilst a complete pathological response in the breast is generally associated with an axillary response, residual axillary disease after primary chemotherapy affects overall survival adversely1 and locoregional failure is associated with poor outcome2. The authors cite the NSABP B-04 study to support the hypothesis that delayed axillary node dissection in patients who had no axillary surgery did not impact on survival, but, in that study, 35 per cent of specimens contained involved axillary nodes. A more recent series reported low recurrence rates in patients with an untreated axilla after a positive SLNB of 1·4 per cent compared to 0·18 per cent in the treated axilla, a statistically significant finding, but with short follow-up and varying radiotherapy techniques as potential confounding variables3. We contend that this meta-analysis should not be interpreted as a standard for routine SLNB after primary chemotherapy. As SLNB is cascaded via the New Start Programme through the UK, women who have had primary chemotherapy should not be included in the validation process of surgeon training.
No takes yet. Share an insight, caveat, or question.
Gerald Gui (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: